Cargando…

Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities

BACKGROUND: Patients with lung cancer and interstitial lung disease treated with radiotherapy are at risk of developing radiation pneumonitis. However, the association between interstitial lung abnormalities (ILAs) and radiation pneumonitis in patients with limited-stage small-cell lung cancer (LS-S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Haruki, Wakuda, Kazushige, Naito, Tateaki, Mamesaya, Nobuaki, Omori, Shota, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Endo, Masahiro, Harada, Hideyuki, Gon, Yasuhiro, Takahashi, Toshiaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972232/ https://www.ncbi.nlm.nih.gov/pubmed/33731123 http://dx.doi.org/10.1186/s13014-021-01780-y

Ejemplares similares

Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy
por: Kobayashi, Haruki, et al.
Publicado: (2018)

Efficacy of prophylactic cranial irradiation in patients with limited-disease small-cell lung cancer who were confirmed to have no brain metastasis via magnetic resonance imaging after initial chemoradiotherapy
por: Mamesaya, Nobuaki, et al.
Publicado: (2018)

Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy
por: Miyawaki, Taichi, et al.
Publicado: (2020)

Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
por: Inoue, Hiroto, et al.
Publicado: (2020)

Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status
por: Mamesaya, Nobuaki, et al.
Publicado: (2023)

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
por: Nishimura, Ari, et al.
Publicado: (2021)

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
por: Miyawaki, Taichi, et al.
Publicado: (2021)

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
por: Kawamura, Takahisa, et al.
Publicado: (2019)

Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2020)

Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation
por: Kodama, Hiroaki, et al.
Publicado: (2021)

Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis
por: Takinami, Masaki, et al.
Publicado: (2021)

Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer
por: Miyawaki, Taichi, et al.
Publicado: (2022)

Acquired immunodeficiency associated with thymoma: a case report
por: Kawamura, Takahisa, et al.
Publicado: (2019)

Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer
por: Miyawaki, Taichi, et al.
Publicado: (2022)

Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy
por: Doshita, Kosei, et al.
Publicado: (2022)

Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy
por: Kasahara, Norimitsu, et al.
Publicado: (2015)

Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2022)

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
por: Miyawaki, Taichi, et al.
Publicado: (2020)

Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study
por: Mitsuya, Koichi, et al.
Publicado: (2019)

Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
por: Kawamura, Takahisa, et al.
Publicado: (2016)

The effects of advanced age and serum α(1)‐acid glycoprotein on docetaxel unbound exposure and dose‐limiting toxicity in cancer patients
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2017)

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Akamatsu, Hiroaki, et al.
Publicado: (2014)

Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
por: Mamesaya, Nobuaki, et al.
Publicado: (2016)

Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter
por: Watanabe, Masaru, et al.
Publicado: (2018)

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients
por: Ko, Ryo, et al.
Publicado: (2016)

Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy
por: Imai, Hisao, et al.
Publicado: (2015)

Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study
por: Ono, Akira, et al.
Publicado: (2013)

Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non–small-cell lung cancer
por: Naito, Tateaki, et al.
Publicado: (2017)

Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study
por: Naito, Tateaki, et al.
Publicado: (2017)

ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non‐small cell lung cancer
por: Harada, Hideyuki, et al.
Publicado: (2016)

Primary malignant melanoma of the trachea: A case report
por: IMAI, HISAO, et al.
Publicado: (2015)

Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer: A single-center observational study
por: Aso, Sakiko, et al.
Publicado: (2022)

Days Spent at Home near the End of Life in Japanese Elderly Patients with Lung Cancer: Post hoc Analysis of A Prospective Study
por: Notsu, Mikako, et al.
Publicado: (2021)

Effectiveness of afatinib in lung cancer with paralytic ileus due to peritoneal carcinomatosis
por: Kobayashi, Haruki, et al.
Publicado: (2016)

Impact of Physical Inactivity on the Risk of Disability and Hospitalization in Older Patients with Advanced Lung Cancer
por: Yonenaga, Yusuke, et al.
Publicado: (2021)

Characterization of tumour mutation burden in patients with non‐small cell lung cancer and interstitial lung disease
por: Kobayashi, Haruki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3a8rvk62hdvev7r82ng2k5afbb